Launches AI project for alcoholic chronic liver disease based on the microbiome

AIDOT (CEO Jeong Jae-hoon) announced on the 2nd that it has been selected as a Regulatory Free Zone project operator within the Gangwon Precision Medicine Industry Regulatory Free Zone, which was finally approved by the Regulatory Free Zone Committee chaired by Prime Minister Kim Boo-kyum. The project aims to enable early AI-based screening for patients with chronic alcoholic liver disease through analysis of human-derived materials.

AIDOT has conducted preliminary research for more than one year with a team led by Professor Seok Ki-tae of the Division of Gastroenterology at Hallym University Chuncheon Sacred Heart Hospital. Through this regulatory free-zone project, regulatory exceptions will be applied, making it possible to reuse information from human-derived materials that are collected and analyzed through microbiome analysis. The company plans to complete solution advancement to a stage ready for immediate commercialization and to pursue MFDS certification in Korea.

Among the regulatory special measures under the Gangwon precision medicine framework, a deferral of the new medical technology assessment period will also be implemented, and demonstration special provisions will proceed immediately after MFDS certification. Based on these outcomes, the company aims to achieve early global commercialization by mobilizing its overseas network.

Professor Seok Ki-tae said, “In the course of preliminary research with AIDOT, we confirmed that by effectively preprocessing big data from microbiome analysis, it is possible to detect liver disease risk at an early stage.”

He emphasized, “This will lead to innovative progress in early liver disease screening, and in particular, it can greatly contribute to reducing all social costs arising from alcoholic liver disease.”

CEO Jeong Jae-hoon said, “This project will become a core medical business within AIDOT’s pipeline,” adding, “By defining early detection of alcoholic liver disease risk groups as a concrete target condition within the globally validated and rapidly developing microbiome treatment market, we will commercialize the first AI-based microbiome genomic analysis solution and take the lead in the global market.”

He added, “Through domestic MFDS certification, we will work so that primary and secondary medical institutions can diagnose and predict alcoholic liver disease using only a simple stool test.”

Published: July 2, 2021 / SisaPrime / Reporter Park Si-na